Addex awarded Michael J. Fox Foundation grant

Wednesday 8 September 2010

Addex Pharmaceuticals Ltd of Switzerland has been awarded a $900,000 grant from the Michael J. Fox Foundation in the US to help fund a Phase 2 study of its candidate treatment for Parkinson’s disease levodopa-induced dyskinesia, ADX48621.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland